The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Systemic AA amyloidosis is a serious complication of many chronic inflammatory disorders. Its association with Crohn's disease implies that the inflammatory burden is high enough for amyloid fibrils to form deposits in tissues. A case is presented in which this complication occurred while the patient was clinically well, with biological and endoscopic markers showing an inactive or mildly active disease...
Crohn’s disease is a chronic inflammatory bowel disease characterized by transmural, granulomatous inflammation. In paediatric-onset Crohn’s disease, the most frequent clinical features are abdominal pain, diarrhoea, fatigue and weight loss. Delayed puberty, growth retardation and osteoporosis might, however, be the predominant signs of the disease. This paper reports the case of a 13-year-old girl...
Basiliximab (Simulect®) is a recombinant chimeric murine/human IgG1 monoclonal anti-interleukin-2 receptor antibody that is indicated for the prevention of acute organ rejection in adult and pediatric renal transplant recipients in combination with other immunosuppressive agents. Induction therapy with two doses (day 0 and day 4) of intravenous basiliximab as part of double- or triple-immunotherapy...
Monoclonal antibodies (mAbs) have complex pharmacology; pharmacokinetics and pharmacodynamics depend on mAb structure and target antigen. mAbs targeting soluble antigens often exhibit linear phar-macokinetic behavior, whereas mAbs targeting cell surface antigens frequently exhibit nonlinear behavior due to receptor-mediated clearance. Where nonlinear kinetics exist, clearance can change due to receptor...
Imiglucerase is a recombinant formulation of human glucocerebrosidase, which is administered to patients with Gaucher disease (GD) as enzyme replacement therapy (ERT). Imiglucerase is generated from transduced Chinese hamster ovary cells, and modified by sequential deglycosylation of its carbohydrate side chains to expose α-mannosyl residues that mediate the uptake of the intravenously infused enzyme...
Perianal complications occur in approximately 33% of patients with Crohn's disease, and may be the most prominent or even the presenting complaint suggestive of a diagnosis of Crohn's disease. A case is reported of severe perianal Crohn's disease with anal destruction and incontinence that developed after perianal surgery. Healing of perianal lesions and recovery of anal function was achieved with...
In patients with inflammatory bowel disease (IBD) the prevalence of ankylosing spondylitis is 4–10%, and approximately 5–10% of ankylosing spondylitis patients have concomitant IBD. The correct recognition of spondyloarthritides is essential in order to identify common therapeutic strategies, especially in the era of new biological therapies such as infliximab. This paper reports a case of a patient...
In this report we describe a case of a 19-year-old woman with a severe to fulminant steroid-resistant ulcerative colitis that was successfully treated with infliximab. Severe to fulminant ulcerative colitis is a potentially life-threatening condition and although the mortality rate has dropped dramatically over the past 40 years, this has not been the case with colectomy which has remained unchanged...
The endothelin system participates in a number of critical biologic pathways, including normal wound healing. In addition, emerging basic science, and animal and human data all suggest that endothelin-1 (EDN1, also known as ET-1) is a potentially important contributor in the pathobiology of fibrosing disorders, including those that affect the lung. For example, EDN1 drives fibroblast activation, proliferation,...
Fistulas are a frequent and serious complication of Crohn's disease. Most of the literature has been focused on perianal fistulas, which are by far the most frequent. The effectiveness of treatment with infliximab in fistulizing Crohn's disease was demonstrated in the ACCENT II trial. In that study, however, all patients had external fistulas, and the majority of those were perianal fistulas. The...
During their development and administration, protein-based drugs routinely display suboptimal therapeutic efficacies due to their poor physicochemical and pharmacological properties. These innate liabilities have driven the development of molecular strategies to improve the therapeutic behavior of protein drugs. Among the currently developed approaches, glycoengineering is one of the most promising,...
Inflammatory bowel disease (IBD), most commonly referring to Crohn’s disease and ulcerative colitis, is a chronic and disabling condition with an increasing incidence in southern Europe. The etiology of IBD remains unknown, but the characteristic disproportionate inflammatory response in the gut may develop through various mechanisms at the cellular and subcellular level. Tumor necrosis factor (TNF)...
Infliximab is an effective agent in the treatment of patients with Crohn’s disease. Therapy with infliximab is generally well tolerated but there are concerns about its effects on the incidence of cancer. This case report refers to a 47-year-old patient with long-standing Crohn’s disease, without a family history of colorectal cancer, who had a previous diagnosis of low-grade dysplasia that was not...
Infliximab and adalimumab are anti-tumor necrosis factor (TNF) alpha agents used for treating Crohn’s disease. Autoimmune hepatitis (AIH) is a rare complication of treatment with these drugs. We report on a case of AIH in a patient with Crohn’s disease treated with infliximab who fully recovered after drug withdrawal. More interestingly, because there were no other treatment options, the patient was...
Recent advances in understanding the biologic mechanisms underlying cancer development have driven the design of new therapeutic approaches, termed ‘targeted therapies’, that selectively interfere with molecules or pathways involved in tumor growth and progression. Inactivation of growth factors and their receptors on tumor cells as well as the inhibition of oncogenic tyrosine kinase pathways and...
The concept of using bispecific antibodies to retarget immune effector cells for cancer therapy was conceived more than 20 years ago. However, initial clinical studies were rather disappointing mainly due to low efficacy, severe adverse effects and immunogenicity of the bispecific antibodies. A deeper understanding of effector cell biology and especially developments in the field of antibody engineering...
The need for new and improved pharmacotherapies in medicine, high late-stage compound attrition in drug discovery, and upcoming patent expirations is driving interest by the pharmaceutical industry in pluripotent stem cells for in vitro modeling and early-stage testing of toxicity and target engagement. In particular, human embryonic and induced pluripotent stem cells represent potentially cost-effective...
The high-risk types of human papillomavirus (HPV) have been found to be associated with most cervical cancers and play an essential role in the pathogenesis of the disease. Despite recent advances in preventive HPV vaccine development, such preventive vaccines are unlikely to reduce the prevalence of HPV infections within the next few years, due to their cost and limited availability in developing...
Background Colon cancer is the third and fourth most prevalent cancer among Iranian men and women, respectively. Suicide gene therapy is one of the alternative therapeutic modalities for cancer. The application of specific promoters for therapeutic genes should decrease the adverse effects of this modality. Objectives The combined aims of this study were to design a specific suicide gene therapy...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.